Analyst firms · Oppenheimer · SRPT
Oppenheimer SRPT price target and rating history
Sarepta Therapeutics Inc. (SRPT) · Health Care
Oppenheimer rates Sarepta Therapeutics Inc. (SRPT) Outperform with a $37 price target, as of its latest action on Jul 29, 2025. It has published 4 rating actions on SRPT since December 2021, including 3 upgrades and 1 downgrade. Across 4 firms with a SRPT price target in the last 12 months, the median target is $23.50.
- Current rating
- Outperform
- Price target
- $37
- Median target, all firms
- $23.50
- Actions on SRPT
- 4
Oppenheimer price target on SRPT
Every Oppenheimer rating on SRPT
- Jul 29, 2025
- May 14, 2024
- Oct 31, 2023
- Dec 9, 2021
How other firms rate SRPT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Deutsche Bank | Hold | $18 | Nov 10, 2026 |
| Wolfe Research | Outperform | $27 | Jul 9, 2026 |
| Barclays | Equal Weight | $20 | Jan 28, 2026 |
| Wedbush | Outperform | $32 | Dec 9, 2025 |
Questions about Oppenheimer and SRPT
- What is Oppenheimer's price target for SRPT?
- Oppenheimer's latest stated price target for Sarepta Therapeutics Inc. (SRPT) is $37, from its action on Jul 29, 2025.
- What is Oppenheimer's rating on SRPT?
- Oppenheimer rates SRPT Outperform, a bullish rating, as of Jul 29, 2025.
- When did Oppenheimer last change its view on SRPT?
- On Jul 29, 2025, Oppenheimer upgrades to Outperform from Perform, price target $37.
- How does Oppenheimer's SRPT target compare with other analysts?
- Across 4 firms with a SRPT price target in the last 12 months, the median target is $23.50.
More SRPT rating histories
- Deutsche Bank4
- Barclays4
- BMO Capital Markets3
- H.C. Wainwright4
- Citigroup4
- Needham5
- Morgan Stanley6
- Cantor Fitzgerald4
- RBC Capital Markets5
- Credit Suisse3
All Oppenheimer ratingsSRPT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.